Introduction
============

Protein diversity is essential for yielding the remarkable regulatory and functional multiformity observed in human cells. A prevalent mechanism for protein diversity is the alternative processing and modification of precursor mRNA ([@b1-or-40-04-2014]). Alternative mRNA splicing (AS) is a regulated process that occurs in \>95% of multi-exon human genes ([@b2-or-40-04-2014],[@b3-or-40-04-2014]), resulting in an enormous amount of flexibility in the regulation of gene function and protein diversity. Recent extensive genomic and functional studies have firmly established the critical role of AS in cancer ([@b4-or-40-04-2014]--[@b6-or-40-04-2014]). The major mechanism may be the involvement of AS in a full spectrum of oncogenic processes, including cell proliferation, apoptosis, hypoxia, angiogenesis, immune escape and metastasis ([@b6-or-40-04-2014],[@b7-or-40-04-2014]). In addition, a transcriptome-wide change in AS programming during epithelial-mesenchymal transition also serves an important role in cancer cell invasion and metastasis ([@b8-or-40-04-2014],[@b9-or-40-04-2014]).

Gastric cancer (GC) is a major global health threat and the third leading cause of cancer-associated mortality worldwide ([@b10-or-40-04-2014]). In addition to DNA sequence alterations ([@b11-or-40-04-2014],[@b12-or-40-04-2014]), epigenetic alterations have also been extensively studied as major players in GC pathogenesis, including DNA methylation ([@b13-or-40-04-2014]), histone modifications (acetylation and methylation) ([@b14-or-40-04-2014]), expression of GC-associated microRNAs ([@b15-or-40-04-2014]) and long non-coding RNAs ([@b16-or-40-04-2014]). However, there have been relatively limited efforts to explore the mechanism of AS involved in the pathogenesis and progression of GC.

The Cancer Genome Atlas (TCGA) project provides abundant sources for the investigation of AS patterns in cancer, including data on the exon, splice and transcript isoform levels, available via the Genomic Data Commons (GDC; <http://gdc.cancer.gov/>). To date, systematic analyses have been performed to reveal the associations of the copy number variation, DNA methylation, gene expression and microRNA expression profiles with the survival of cancer patient ([@b17-or-40-04-2014],[@b18-or-40-04-2014]). However, the majority of RNA sequencing studies focus on identifying cancer-specific AS events ([@b19-or-40-04-2014],[@b20-or-40-04-2014]). A recent analysis of TCGA RNA sequencing data identified 163 cancer-specific AS events for three cancer types, among which five were found to be potentially associated with survival in breast cancer ([@b21-or-40-04-2014]). There has been a lack of studies, however, that comprehensively analyze systematic cancer survival associated with AS at individual exon resolution, particularly in GC.

Recently, Armero *et al* ([@b22-or-40-04-2014]) provided the first comprehensive portrait of global modifications in the cellular RNA splicing signatures that occur in Epstein-Barr virus (EBV)-associated GC. Since EBV infection is associated with only 10% of all GC cases reported worldwide ([@b23-or-40-04-2014]), the present study aimed to systematically analyze the unclassified GC-specific AS events in the TCGA-stomach adenocarcinoma (STAD) cohort. Furthermore, survival-associated AS events were identified, and gene models with clinical parameters were constructed as prognosis predictors for GC patients.

Materials and methods
=====================

### TCGA RNA sequencing data and processing

RNA sequencing read counts and medical information of GC patients, namely the TCGA-STAD cohort, were downloaded from TCGA data portal (<https://tcga-data.nci.nih.gov/>). The TCGA dataset provided the number of RNA sequencing read counts on the splice junctions as part of the level 3 RNA sequencing data. As shown in [Fig. 1](#f1-or-40-04-2014){ref-type="fig"}, there are seven types of splice events, as follows: Exon skipping (ES), mutually exclusive exons (ME), retained intron (RI), alternative promoter (AP), alternative terminator (AT), alternative donor site (AD) and alternative acceptor site (AA). For each ES event defined in the Ensembl annotations, the read counts were identified for exon-inclusion and skipping splice junctions.

### Cancer specific mRNA splice variations analysis

SpliceSeq tool (version 2.0) (<http://bioinformatics.mdanderson.org/main/SpliceSeq:Methods>) was applied to analyze the mRNA splicing patterns of TCGA-STAD samples ([@b24-or-40-04-2014]), which started with a reference model for each gene constructed from all the protein-coding transcripts in the Ensembl database. The percent spliced in (PSI) index indicates how efficiently sequences of interest are spliced into transcripts, with values ranging between 0 and 1 ([@b25-or-40-04-2014]). The PSI values were calculated for the seven types of AS events.

To identify possibly abnormal AS events in GC, comparisons of the PSI values were conducted between GC and normal samples (415 STAD tumors vs. 37 normal controls). Student\'s t-test, followed by an adjustment of the P-value (Benjamini-Hochberg method for multiple comparisons), was applied, and P\<0.001 was considered to denote a statistically significant difference.

UpSet plot, a novel visualization technique for the quantitative analysis of interactive sets ([@b26-or-40-04-2014]), was also used to analyze the intersections between seven types of AS in GC.

### Survival analysis

Only 373 GC patients with an overall survival (OS) of ≥30 days were enrolled in the survival analysis. Clinical covariates contained age, sex and the pathologic T stage, N stage, M stage and TNM stage ([@b27-or-40-04-2014]), as characterized by TCGA consortium (summarized in [Table I](#tI-or-40-04-2014){ref-type="table"}). For each AS events, GC patients were divided into two groups using the median as a cutoff value. The association between AS events and OS were evaluated by univariate Cox regression analysis. In addition, multivariate Cox regression was conducted to remove any genes that may not be independent factors in the prognostic models. Following the construction of each multivariate model, a high-risk status for GC-related death was defined when the right side of the Cox regression equation was \>0, while low risk was defined when the value in the right side of the equation was \<0. Based on the definition of high and low risk, survival curves were constructed to evaluate the performance of prognostic models.

### Gene Ontology (GO) analysis

GO enrichment analysis (<https://david.ncifcrf.gov/>) was conducted to explore the functions of differentially spliced genes identified in the present study. Furthermore, the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<http://www.genome.ad.jp/kegg/>) was used to assess the potential functions of these target genes in pathways. Fisher\'s exact test was used to determine the GO category and GO annotation list.

### Statistical analysis

All statistical analyses were performed using R/Bioconductor software (version 3.4.1; <http://www.bioconductor.org/>). All statistical tests were two-sided, and P=0.05 was considered as the threshold for a statistically significant difference, unless otherwise stated.

Results
=======

### Integrated mRNA splice variant profile in the TCGA-STAD cohort

Integrated mRNA splice variant profiles were explored in depth for 452 tissues in the STAD cohort. In total, 60,754 mRNA splice variants were detected in 10,611 genes, comprised of 31,730 ES events in 6,973 genes, 226 ME events in 219 genes, 2,944 RI events in 1,956 genes, 10,005 AP events in 4,025 genes, 8,393 AT events in 3,666 genes, 3,450 AD events in 2,401 genes and 4,006 AA events in 2,799 genes ([Fig. 2](#f2-or-40-04-2014){ref-type="fig"}). The findings of the current study indicated that AS may be universal in human multi-exon genes. Furthermore, the results demonstrated that over half of the mRNA splice variants were ES variants.

### Analysis of cancer-specific mRNA splice variants

To discern any differences in mRNA splice variants, the PSI values of mRNA splice variants in STAD tumor tissues were compared with those in normal tissues ([Fig. 2](#f2-or-40-04-2014){ref-type="fig"}). Since only 7 ME variants in 7 genes were detected to be differentially spliced in GC tissues compared with normal tissues, the study focused on the other six modes of AS for a more detailed analysis. For instance, 2,717 ES variants that belong to 402 genes were found to be differentially spliced (P\<0.001; fold change \>2). Thus, on average, a gene may have more than one cancer-specific ES event, indicating a diverse involvement of ES in GC.

The top ranked GC-specific splice genes were labeled in the volcano plots, with the exception of ME with only 7 variants ([Fig. 3](#f3-or-40-04-2014){ref-type="fig"}). Furthermore, it was observed that there were a few genes that had more than one type of mRNA splice variant and were differentially spliced in GC. The intersection of gene sets is visualized in [Fig. 4](#f4-or-40-04-2014){ref-type="fig"}. For instance, RPS6 and UBE2C had four types of variants (ES, RI, AD and AA) that were differentially spliced in GC. In addition, the ES, AT, AD and AA variants in gene RPS3A were also differentially spliced.

### GO and KEGG pathway analysis of cancer-specific differentially spliced genes

Through GO analysis, genes were organized into hierarchical categories to uncover gene regulatory networks on the basis of biological process (excluding the ME events). It was observed that, among these differentially spliced genes, 1,320 are involved in biological processes, 1,380 in cellular components and 1,149 in molecular functions ([Fig 5A-C](#f5-or-40-04-2014){ref-type="fig"}).

To further specify and identify target mRNAs (excluding the ME events), significant pathways of differentially spliced mRNAs were analyzed using the KEGG database ([Fig. 5D](#f5-or-40-04-2014){ref-type="fig"}). This analysis revealed that GC-specific ES genes were focused in six pathways, including *Salmonella* infection, bacterial invasion of epithelial cells, shigellosis, pathogenic *Escherichia coli* infection, ribosome and adrenergic signaling in cardiomyocytes. Ribosome was the only significantly enriched network for AA, AD, AT, ES and RI variants.

### Association of OS with mRNA splice variants in the TCGA-STAD cohort

Univariate survival tests were first conducted to assess the correlation between clinical parameters and OS in the STAD cohort. The age, T stage, N stage, M stage and TNM stage were significantly associated with OS. Next, univariate survival analysis for OS was conducted using the integrated mRNA splice variants profiles in the STAD cohort. The univariate survival analyses identified that 1,168 ES, 16 ME, 138 RI, 675 AP, 434 AT, 186 AD and 170 AA events were statistically associated with OS. The top 20 genes that were most significantly associated with survival in the six types of AS are presented in [Fig. 6](#f6-or-40-04-2014){ref-type="fig"} (excluding the ME events).

### Integrated STAD risk predictor: Prognostic gene sets

Subsequent to determining the candidate genes across the seven types of mRNA splice variants, multivariate Cox regression was separately applied to the candidate gene sets for each of the six types of AS ([Fig. 2](#f2-or-40-04-2014){ref-type="fig"}). The ES variants in 25 genes were found to be independent prognostic factors in the survival of STAD patients. Notably, MAPKBP1 was one of the most significant independent prognostic factors \[hazard ratio (HR), 116.77; 95% confidence interval (95% CI), 15.66--870.87; P\<0.001\]. The age, T stage, N stage and M stage were also independent prognostic factors in the models. Similarly, numerous genes were identified as independent prognostic factors in the other six types of mRNA splice variants. The specific AS events of genes involved in the final models are listed in [Table II](#tII-or-40-04-2014){ref-type="table"}.

Based on the aforementioned prognostic models, Kaplan-Meier survival plots were generated to test the performance of these models as shown in [Fig. 7](#f7-or-40-04-2014){ref-type="fig"} (excluding ME). All six mRNA splice variant prognostic models were significantly associated with the OS of GC patients (all P\<0.05). Furthermore, the prediction models constructed for the splice variants ES, AP, AT, AD and AA were good, since evident gaps between the curves of high-risk and low-risk patients were observed.

Discussion
==========

AS generally allows cells to generate substantial mRNA and protein isoforms with diverse regulatory and functional properties, which may also facilitate the survival, proliferation and metastasis of cancer cells ([@b6-or-40-04-2014],[@b7-or-40-04-2014]). The present study reported a comprehensive transcriptome-wide analysis of the AS profiling landscape for GC, and identified a significant association between AS and the GC clinical outcome. Through an analysis of the RNA-Seq data of individuals in the TCGA-STAD cohort, a total of 60,754 mRNA splice variants were detected in 10,611 genes. Recently, Tsai *et al* ([@b21-or-40-04-2014]) reported that there were individually 65,152, 70,342 and 70,637 AS events in breast, liver and lung cancer, respectively, all of which have a slightly higher number of AS events compared with that reported for GC in the present study.

Systematic identification and analysis of cancer-specific AS events was also performed in the current study, using TCGA-STAD data. The results revealed that there are thousands of AS events significantly associated with GC, involving multiple genes whose splicing is known to serve a critical role in cancer development, such as CD44 ([@b28-or-40-04-2014]). Several studies have demonstrated that polymorphisms in CD44 are associated with a risk for several types of cancer, including breast cancer ([@b29-or-40-04-2014]), colorectal cancer ([@b30-or-40-04-2014]) and GC ([@b31-or-40-04-2014]). In the present study, CD44 was differentially spliced between GC and normal tissues, and the main splicing modes were ES and AA. It was also observed that one type of ES events for CD44 was negatively associated with the survival in GC. However, the AS mechanisms for CD44 have yet to be explicitly defined, and the role of different CD44 spliced isoforms in the development and metastasis of GC should be more clearly elucidated in future studies. Conversely, several AS events of genes with well-known roles in cancer development were not identified by our procedure, possibly due to the highly stringent inclusion criteria applied in the present study. For instance, GC-specific AS genes in the present study did not include Bcl-xL, whose splicing is known to control cell apoptosis in multiple tumors ([@b32-or-40-04-2014]). In addition, CDH1 was also not identified as a GC-specific AS gene, yet CDH1 exon 11 skipping has been reported in leukemia cells, and head and neck cancer cells ([@b33-or-40-04-2014],[@b34-or-40-04-2014]), while a fragment lacking the final 83 base pairs of exon 8 in CDH1 was frequently detected in Chinese GC patients ([@b35-or-40-04-2014]). The fold change of Bcl-xL and CDH1 was not, however, large enough to pass the significance thresholds in the present analysis. It is expected that additional cancer-specific genes could be identified if these criteria are relaxed. Furthermore, the P-value of AS events was required to be \<0.001, which may cause certain uncommon events to be omitted in the current study.

Notably, RPS6 and UBE2C were found to have four splicing modes (ES, RI, AD and AA) of variants that were differentially spliced in GC. RPS6, a component of the 40S ribosomal subunit, is regarded to be involved in the translation of specific mRNAs, as well as a regulator of cellular metabolisms, survival and proliferation ([@b36-or-40-04-2014]). Several studies have reported the overexpression and activation of RPS6 in esophageal squamous cell carcinoma ([@b37-or-40-04-2014]), lung cancer ([@b38-or-40-04-2014]) and breast cancer ([@b39-or-40-04-2014]). Furthermore, the present study demonstrated that increased ES events in RPS6 were associated with poor prognosis. UBE2C encodes a member of the E2 ubiquitin-conjugating enzyme family, which is involved in the destruction of mitotic cyclins and cell cycle progression ([@b40-or-40-04-2014]). Overexpression of UBE2C is associated with worse clinical outcomes in a number of cancer types, including GC ([@b41-or-40-04-2014]). MAPKBP1, acting as a scaffold protein, facilitates the polyubiquitination of TNF-receptor associated factor 2, leading to the TGF-β-activated kinase 1-mediated activation of nuclear factor-κB ([@b42-or-40-04-2014],[@b43-or-40-04-2014]). The results of the current study also revealed that MAPKBP1 was one of the most significant independent prognostic factors. Fu *et al* ([@b44-or-40-04-2014]) reported the prognostic relevance of MAPKBP1 expression in cytogenetically normal acute myeloid leukemia. This evidence probably suggests the functional and clinical relevance of these genes in the survival-associated AS events. While certain of these events may reflect a correlation but may not have a causal effect on the survival of GC patients, others may serve an active role in regulating the cancer cell phenotypes, cancer development and cancer prognosis. Therefore, AS events for these marked genes should be investigated further to elucidate their impact on the development and prognosis of GC.

Currently, AS has been considered to be generally regulated by multiple cis-acting splicing regulatory elements that are specifically bound by *trans*-acting splicing factors to enhance or inhibit the use of nearby splice sites ([@b45-or-40-04-2014],[@b46-or-40-04-2014]). AS events can respond not only to various signaling pathways that target splicing mechanisms, but can also be influenced by transcription factors and chromatin structure ([@b47-or-40-04-2014]). Small interfering RNAs have been reported to trigger AS events in human cells through transcriptional gene silencing pathways ([@b48-or-40-04-2014]). MicroRNAs can also serve an important role in the regulation of AS. For instance, miR-124 promotes neuronal differentiation by targeting the PTBP1 splicing repressor ([@b49-or-40-04-2014]). Shukla *et al* ([@b50-or-40-04-2014]) reported that DNA methylation can regulate AS in CD45 exon 5. Furthermore, the expression of numerous cellular splicing factors has been reported to be dysregulated in various human diseases. Armero *et al* ([@b22-or-40-04-2014]) detected several changes in the expression levels and/or splicing patterns of cellular splicing factors in EBV-negative GC tissues, including CDK10, MBNL1 and RBFOX2. Notably, recent data demonstrated a key role for RBFOX2 and MBNL1, which seem to account for numerous splicing alterations in breast, lung and prostate cancer ([@b51-or-40-04-2014]). The current study also identified that ES events in RBFOX2 and MBNL1 were significantly different in GC samples. Although a few known factors regulating AS events can be listed, it is likely that there are numerous other regulators awaiting identification and validation.

In conclusion, the present study generated a common set of cancer-specific and survival-associated AS events in GC. Furthermore, the results demonstrated that a core set of AS events can be potentially applied to build predictive models for the survival of GC patients with a higher accuracy. This further demonstrates the potential biological relevance and clinical utility of these identified AS events. Ultimately, certain RNA splicing isoforms may eventually be used as diagnostic or prognostic biomarkers, and even as novel therapeutic targets.
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![Illustration of the seven types of alternative splicing in the present study, including: (A) Exon skipping; (B) mutually exclusive exons; (C) retained intron; (D) alternative promoter; (E) alternative terminator; (F) alternative donor site; and (G) alternative acceptor site.](OR-40-04-2014-g00){#f1-or-40-04-2014}

![Flow chart of the study design. AA, alternativee acceptor site; AD, alternative donor site; AP, alternativee promoter; AT, alternative terminator; ES, exon skipping; ME, mutually exclusive exons; RI, retained intron; TCGA, The Cancer Genome Atlas; STAD, stomach adenocarcinoma.](OR-40-04-2014-g01){#f2-or-40-04-2014}

![Volcano plots for the six types of alternative splicing with top ranked cancer-specific splice genes. (A) ES, (B) RI, (C) AP, (D) AT, (E) AD and (F) AA event plots are shown. The y-axis represents the negative log~10~ P-values, while the x-axis represents the log~2~ of the fold change for every type of alternative splicing. The red dots indicate that alternative splicing variants were found to be significantly differentially spliced between GC tissues and normal tissues. The gene names of top ranked cancer-specific splice variants are shown. AA, alternative acceptor site; AD, alternative donor site; AP, alternative promoter; AT, alternative terminator; ES, exon skipping; RI, retained intron.](OR-40-04-2014-g02){#f3-or-40-04-2014}

![UpSet plots in STAD, showing the interactions between the seven types of GC-specific alternative splicing events in STAD. One gene may have up to four types of alternative splicing that are differentially spliced in STAD. AA, alternative acceptor site; AD, alternative donor site; AP, alternative promoter; AT, alternative terminator; ES, exon skipping; ME, mutually exclusive exons; RI, retained intron; STAD, stomach adenocarcinoma.](OR-40-04-2014-g03){#f4-or-40-04-2014}

![Go and KEGG analysis of differentially spliced genes. (A) Biological process. (B) Cellular components. (C) Molecular functions. (D) KEGG pathway.](OR-40-04-2014-g04){#f5-or-40-04-2014}

![Forrest plots of hazard ratios for survival-associated alternative events in stomach adenocarcinoma. Hazard ratios of the top 20 genes with survival-associated (A) ES, (B) RI, (C) AP, (D) AT, (E) AD and (F) AA events. AA, alternative acceptor site; AD, alternative donor site; AP, alternative promoter; AT, alternative terminator; ES, exon skipping; ME, mutually exclusive exons; RI, retained intron.](OR-40-04-2014-g05){#f6-or-40-04-2014}

![Kaplan-Meier prognostic predictors for gastric cancer. Prognostic predictor models were constructed according to the (A) ES, (B) RI, (C) AP, (D) AT, (E) AD and (F) AA events in stomach adenocarcinoma. AA, alternative acceptor site; AD, alternative donor site; AP, alternative promoter; AT, alternative terminator; ES, exon skipping; ME, mutually exclusive exons; RI, retained intron.](OR-40-04-2014-g06){#f7-or-40-04-2014}

###### 

Clinical parameters of patients in the stomach adenocarcinoma cohort obtained from The Cancer Genome Atlas (n=373).

  Parameter                                                    Value
  ------------------------------------------------------------ -------------
  Age (years)^[a](#tfn1-or-40-04-2014){ref-type="table-fn"}^   67 (30--90)
  Sex (male)                                                   245
  T stage                                                      
    T1                                                         18
    T2                                                         82
    T3                                                         169
    T4                                                         100
    TX                                                         4
  N stage^[b](#tfn2-or-40-04-2014){ref-type="table-fn"}^       
    N0                                                         111
    N1                                                         105
    N2                                                         72
    N3                                                         75
    NX                                                         9
  M stage                                                      
    M0                                                         338
    M1                                                         22
    MX                                                         13
  TNM stage^[c](#tfn3-or-40-04-2014){ref-type="table-fn"}^     
    I                                                          50
    II                                                         118
    III                                                        157
    IV                                                         36

Age data were not available for 6 individuals

pathologic N stage was not available in 1 case

pathologic TNM stage was not available for 12 individuals. Age is reported as the median (range).

###### 

List of survival-associated splicing factors of genes in multivariate Cox analysis.

  Alternative splicing   Genes
  ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AA                     CBX7, DHPS, DYNLL1, LMO7, MORF4L2, RPS21, SCYL1, SHQ1, SMUG1, SUN2, TCTN1, TNIP1
  AD                     BMP4, C1QC, DAGLB, E2F5, GK5, IRF9, LYRM9, MARVELD3, MGME1, MT1F, NFATC1, NOB1, RALGPS1, TAF1D, TXNDC9, WDR20
  AP                     ALDOA, CCDC64B, CCND3, CLIP3, CTBP2, DALRD3, DCTN1, HOXB3, IL1R1, KDM2B, KIAA1671, MICAL2, NEDD1, NFATC2, NNT, NR2F2, PKM, PLAGL1, RTN4, SGIP1, TCF4, TNFAIP8L1, ZNF544
  AT                     ABCB5, ABCC5, ACAD9, C1orf52, CD300LG, CPED1, DYNLL1, EDA, GHR, IL7R, MRPL30, NOX4, PRTG, REXO2, RMDN2, SLC35G1, SMG8, SPINK5, TSTD2, UQCC1, WNT9B, ZBTB8OS, ZNF407, ZNF680, ZNF846
  ES                     ABI1, ARHGAP4, C14orf80, CD44, EML2, FSTL1, GGA3, GRIPAP1, HPGD, LDB2, MAP4, MAPKBP1, MEF2B, NCOA7, NFATC3, P4HA2, PLAGL1, RHOT1, RQCD1, SAE1, SEC16A, SEC31A, SLC27A2, UBA52, WWP2
  ME                     G3BP1, GRB10, H2AFY, ZDHHC16, ZNF140
  RI                     BICD2, BRWD1, C18orf21, COPZ1, CYHR1, FAU, FOS, METTL3, SMUG1, UBE2V1

AA, alternative acceptor site; AD, alternative donor site; AP, alternative promoter; AT, alternative terminator; ES, exon skipping; ME, mutually exclusive exons; RI, retained intron.
